https://www.thebodypro.com/category/biktarvy-pro/tag/news

The Latest

illustration of person on cliff with arms raised as sun rises/sets

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best Img

Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices -- but Really 2 Are Best

On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.

Bictegravir Approved in the U.S. in New Integrase Inhibitor-Based Fixed-Dose Combination (Biktarvy) Img

Bictegravir Approved in the U.S. in New Integrase Inhibitor-Based Fixed-Dose Combination (Biktarvy)

On Feb. 7, 2018, the U.S. FDA approved a new fixed-dose combination (FDC) containing bictegravir, emtricitabine and tenofovir alafenamide (TAF).

Bictegravir -- It's Coming: A Top HIV Clinical Development of 2017 Img

Bictegravir -- It's Coming: A Top HIV Clinical Development of 2017

Last year's antiretroviral darling was dolutegravir (Tivicay, DTG). Now, the limelight has shifted to its integrase sibling, bictegravir. Requiring no pharmacological boosting, boasting a high barrier to resistance, and in early 2018 available co-for...